Unknown

Dataset Information

0

Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer.


ABSTRACT:

Background

trastuzumab is considered the standard of care for human epidermal growth factor receptor-2 (HER-2+) breast cancer patients. Regardless of the benefits of its use, many early-stage patients eventually recur, and usually, the disease progresses within a year. Since about half of the HER-2+ patients do not respond to trastuzumab, new biomarkers of prognosis and prediction are warranted to allow a better patient stratification. Annexin A1 (ANXA1) was previously reported to contribute to trastuzumab resistance through AKT activation. An association between adenine thymine-rich interactive domain 1A (ARID1A) loss and ANXA1 upregulation was also previously suggested by others.

Methods

in this study, we examined tissue samples from 215 HER-2+ breast cancer patients to investigate the value of ARID1A and ANXA1 protein levels in trastuzumab response prediction and patient outcome. Expression of ARID1A and ANXA1 were assessed by immunohistochemistry.

Results

contrary to what was expected, no inverse association was found between ARID1A and ANXA1 expression. HER-2+ (non-luminal) tumours displayed higher ANXA1 expression than luminal B-like (HER-2+) tumours. Concerning trastuzumab resistance, ARID1A and ANXA1 proteins did not demonstrate predictive value as biomarkers. Nevertheless, an association was depicted between ANXA1 expression and breast cancer mortality and relapse.

Conclusions

overall, our results suggest that ANXA1 may be a useful prognostic marker in HER-2+ patients. Additionally, its ability to discriminate between HER-2+ (non-luminal) and luminal B-like (HER-2+) patients might assist in patient stratification regarding treatment strategy.

SUBMITTER: Silva-Oliveira R 

PROVIDER: S-EPMC7761245 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>trastuzumab is considered the standard of care for human epidermal growth factor receptor-2 (HER-2+) breast cancer patients. Regardless of the benefits of its use, many early-stage patients eventually recur, and usually, the disease progresses within a year. Since about half of the HER-2+ patients do not respond to trastuzumab, new biomarkers of prognosis and prediction are warranted to allow a better patient stratification. Annexin A1 (ANXA1) was previously reported to contri  ...[more]

Similar Datasets

| S-EPMC7341683 | biostudies-literature
| S-EPMC5115774 | biostudies-literature
| S-EPMC5644103 | biostudies-literature
| S-EPMC8209838 | biostudies-literature
| S-EPMC7719290 | biostudies-literature
| S-EPMC6136851 | biostudies-other
| S-EPMC4869259 | biostudies-literature
| S-EPMC5078029 | biostudies-literature
| S-EPMC10730165 | biostudies-literature
| S-EPMC6819570 | biostudies-literature